All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2007-003089-16||Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kina...||2012-06-05||due-trials|
|Completed, but no date||2011-000299-33||Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma||bad-data|
|Reported results||2011-001015-32||A multi-centre, open-label, randomised, twoarm Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary ...||2020-11-26||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2012-004125-24||A prospective randomized Phase III trial of carboplatin/gemcitabing/bevacizumab vs caboplatin/pegylated lipsomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer||2021-01-19||bad-data|
|Ongoing||2017-000202-37||Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer – a randomized Phase III trial Atezolizumab en combinación con Bevacizu...||not-yet-due|
|Ongoing||2018-004207-39||A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. supported by: DIAGNOSTIC PRO...||not-yet-due|
|Ongoing||2020-005101-12||Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in ...||not-yet-due|
|Ongoing||2021-001271-16||Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)||not-yet-due|